TY - JOUR
T1 - 2020 IDEOM Annual Meeting
T2 - Actinic Keratosis Stakeholders Survey Identifies Gaps in Research and Care
AU - Babalola, Folawiyo
AU - Moattari, Cameron
AU - Berman, Brian
AU - Bhatia, Neal
AU - Goldberg, Leonard H.
AU - Gottlieb, Alice
AU - Grada, Ayman
AU - Hanke, C. William
AU - Jagdeo, Jared
AU - Jimenez, Xochitl
AU - Konnikov, Nellie
AU - Martin, George
AU - Maytin, Edward
AU - Milane, Michael
AU - Nestor, Mark S.
AU - Noda, Aliene
AU - Rosen, Ted
AU - Shah, Sana
AU - Willey, Andrea
AU - Yoo, Jane
AU - Zeitouni, Nathalie C.
AU - Siegel, Daniel M.
N1 - Publisher Copyright:
© 2022 Journal of Drugs in Dermatology. All rights reserved.
PY - 2022/2
Y1 - 2022/2
N2 - This is a report of the survey results from the International Dermatology Outcome Measures (IDEOM) actinic keratosis (AK) workgroup. The purpose of the survey was to compile a list of gaps within AK care and management that require refinement. The results were discussed at the IDEOM annual meeting held virtually on October 23-24, 2020. This built a framework with which the AK workgroup, which consisted of physicians, patients, and pharmaceutical scientists, discussed at length in their breakout session at the meeting. The electronic survey was distributed to patients, pharmaceutical scientists, and leading physician experts in the field via email on September 22, 2020, with a deadline of October 2, 2020. The survey consisted of three open-ended prompts concerning key gaps and/or unmet needs in (1) the care of AKs, (2) outcome measurement of AKs in clinical trials and, (3) the measurement of AKs in clinical practice. The results were qualitative, with a response rate of 47%. Responses included reform of outcome measures for clinical trials, a methodology for evaluating the efficacy of preventative measures, and a comparison of treatments to establish a treatment protocol, among other efforts. This paper will also provide a brief overview of the current state of the AK outcome measures, emphasizing the heterogeneity of the measures and detailing the AK workgroup's future efforts to create a reliable and applicable core outcome measure set.
AB - This is a report of the survey results from the International Dermatology Outcome Measures (IDEOM) actinic keratosis (AK) workgroup. The purpose of the survey was to compile a list of gaps within AK care and management that require refinement. The results were discussed at the IDEOM annual meeting held virtually on October 23-24, 2020. This built a framework with which the AK workgroup, which consisted of physicians, patients, and pharmaceutical scientists, discussed at length in their breakout session at the meeting. The electronic survey was distributed to patients, pharmaceutical scientists, and leading physician experts in the field via email on September 22, 2020, with a deadline of October 2, 2020. The survey consisted of three open-ended prompts concerning key gaps and/or unmet needs in (1) the care of AKs, (2) outcome measurement of AKs in clinical trials and, (3) the measurement of AKs in clinical practice. The results were qualitative, with a response rate of 47%. Responses included reform of outcome measures for clinical trials, a methodology for evaluating the efficacy of preventative measures, and a comparison of treatments to establish a treatment protocol, among other efforts. This paper will also provide a brief overview of the current state of the AK outcome measures, emphasizing the heterogeneity of the measures and detailing the AK workgroup's future efforts to create a reliable and applicable core outcome measure set.
UR - http://www.scopus.com/inward/record.url?scp=85124326074&partnerID=8YFLogxK
U2 - 10.36849/JDD.6360
DO - 10.36849/JDD.6360
M3 - Article
C2 - 35133114
AN - SCOPUS:85124326074
SN - 1545-9616
VL - 21
SP - 128
EP - 134
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 2
ER -